Hafslund Nycomed's Omniscan MRI contrast agent has been certifiedfor marketing in Japan, the Oslo, Norway, company reported thismonth. Nycomed said that Omniscan will be launched by DaiichiPharmaceutical, Nycomed's Japanese licensee, as soon as
Hafslund Nycomed's Omniscan MRI contrast agent has been certified
for marketing in Japan, the Oslo, Norway, company reported this
month. Nycomed said that Omniscan will be launched by Daiichi
Pharmaceutical, Nycomed's Japanese licensee, as soon as final
price approval is granted by Japanese authorities. Nycomed added
that it has submitted an application for marketing approval in
Japan for Visipaque, its third-generation x-ray contrast agent.
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).
Study: Mammography AI Leads to 29 Percent Increase in Breast Cancer Detection
February 5th 2025Use of the mammography AI software had a nearly equivalent false positive rate as unassisted radiologist interpretation and resulted in a 44 percent reduction in screen reading workload, according to findings from a randomized controlled trial involving over 105,000 women.